HomeCompareYMZBY vs ABBV

YMZBY vs ABBV: Dividend Comparison 2026

YMZBY yields 2.10% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YMZBY wins by $78.49M in total portfolio value· pulled ahead in Year 4
10 years
YMZBY
YMZBY
● Live price
2.10%
Share price
$180.00
Annual div
$3.77
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.60M
Annual income
$71,997,566.31
Full YMZBY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — YMZBY vs ABBV

📍 YMZBY pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYMZBYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YMZBY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YMZBY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YMZBY
Annual income on $10K today (after 15% tax)
$178.14/yr
After 10yr DRIP, annual income (after tax)
$61,197,931.36/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, YMZBY beats the other by $61,176,875.36/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YMZBY + ABBV for your $10,000?

YMZBY: 50%ABBV: 50%
100% ABBV50/50100% YMZBY
Portfolio after 10yr
$39.35M
Annual income
$36,011,169.04/yr
Blended yield
91.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

YMZBY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
3.2
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YMZBY buys
0
ABBV buys
0
No recent congressional trades found for YMZBY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYMZBYABBV
Forward yield2.10%3.06%
Annual dividend / share$3.77$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$78.60M$102.3K
Annual income after 10y$71,997,566.31$24,771.77
Total dividends collected$78.07M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: YMZBY vs ABBV ($10,000, DRIP)

YearYMZBY PortfolioYMZBY Income/yrABBV PortfolioABBV Income/yrGap
1$11,119$419.15$11,550$430.00$431.00ABBV
2$12,769$871.15$13,472$627.96$703.00ABBV
3$15,532$1,869.87$15,906$926.08$374.00ABBV
4← crossover$20,871$4,251.57$19,071$1,382.55+$1.8KYMZBY
5$33,011$10,678.38$23,302$2,095.81+$9.7KYMZBY
6$66,890$31,568.75$29,150$3,237.93+$37.7KYMZBY
7$191,140$119,567.32$37,536$5,121.41+$153.6KYMZBY
8$843,148$638,628.47$50,079$8,338.38+$793.1KYMZBY
9$6,167,764$5,265,596.25$69,753$14,065.80+$6.10MYMZBY
10$78,597,074$71,997,566.31$102,337$24,771.77+$78.49MYMZBY

YMZBY vs ABBV: Complete Analysis 2026

YMZBYStock

Yamazaki Baking Co., Ltd., through its subsidiaries, manufactures and sells baked goods in Japan. Its products include loaf bread, sweet buns, donuts, hard rolls, and Danish pastries; Japanese, Western style, and rice-derived and based confectionery; processed bread and noodles, prepared rice, and side dishes; and chocolates, candies, stevia-based and other sweeteners, snack foods, and soup and soup stocks, as well as jams, marmalades, jelly and yokan products, and ready-to-eat curries in retort pouches. The company also manufactures biscuits, cookies, crackers, and frozen bread dough; provides coffee and juice under the Yamazaki brand; creams, curry fillings, stuffing for Chinese filled buns, croquettes, meat patties, and mayonnaise products; and prepared mixes for bread, tempura, and fried chicken, as well as sells products procured from other companies. In addition, it is involved in the manufacture and sale of cleaning and disinfecting agents for food production equipment; operation of bread and pastry shops, restaurants, convenience stores, and supermarkets; provision of retail bakery and cafe management, in-store bakery management, general truck transport and freight forwarding, and insurance services; and design of equipment for manufacturing bread and confectionery, installation of production facilities, and other services. Further, the company offers logistics management services; and manufactures and sells stevia-based and other sweeteners. As of December 31, 2021, it operated 1,389 stores. Yamazaki Baking Co., Ltd. was incorporated in 1948 and is headquartered in Tokyo, Japan.

Full YMZBY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this YMZBY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YMZBY vs SCHDYMZBY vs JEPIYMZBY vs OYMZBY vs KOYMZBY vs MAINYMZBY vs JNJYMZBY vs MRKYMZBY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.